Neoadjuvant Sorafenib Treatment of Clear Cell Renal Cell Carcinoma and Release of Circulating Tumor Fragments
Authors:
Open Access
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Rapid Angiogenesis Onset after Discontinuation of Sunitinib Treatment of Renal Cell Carcinoma PatientsClinical Cancer Research, 2012
- Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapyCancer Biology & Therapy, 2011
- VHL and HIF signalling in renal cell carcinogenesisThe Journal of Pathology, 2010
- Neoadjuvant Clinical Trial With Sorafenib for Patients With Stage II or Higher Renal Cell CarcinomaJournal of Clinical Oncology, 2010
- Collective cell migration in morphogenesis, regeneration and cancerNature Reviews Molecular Cell Biology, 2009
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant MetastasisCancer Cell, 2009
- Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigmBJU International, 2008
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialThe Lancet, 2007
- An Invasion-Independent Pathway of Blood-Borne MetastasisThe American Journal of Pathology, 2002
- THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST.The Lancet, 1889